{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:05:24Z","timestamp":1779426324662,"version":"3.53.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07807-4","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:27:30Z","timestamp":1770708450000},"page":"4436-4445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Masumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Mitsunari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Higashijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousei","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"7807_CR1","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s11604-025-01816-3","volume":"43","author":"K Suzuki","year":"2025","unstructured":"Suzuki K, Fujimoto N, Shiota M, Kawakami S, Kimura T, Hashimoto K, et al. Recent advances in drug treatment for prostate cancer. Jpn J Radiol. 2025;43:1618\u201327. https:\/\/doi.org\/10.1007\/s11604-025-01816-3.","journal-title":"Jpn J Radiol"},{"key":"7807_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/jjco\/hyae079","volume":"54","author":"T Kawai","year":"2024","unstructured":"Kawai T, Onozawa M, Taguchi S, Shiota M, Sakamoto S, Yamamoto Y, et al. Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study. Jpn J Clin Oncol. 2024;54:1045\u201351. https:\/\/doi.org\/10.1093\/jjco\/hyae079.","journal-title":"Jpn J Clin Oncol"},{"key":"7807_CR3","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Larsen RH, Foss\u00e5 SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2244.","journal-title":"Clin Cancer Res"},{"key":"7807_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"key":"7807_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1200\/JCO.2011.36.5791","volume":"30","author":"ER Dennis","year":"2012","unstructured":"Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519\u201324. https:\/\/doi.org\/10.1200\/JCO.2011.36.5791.","journal-title":"J Clin Oncol"},{"key":"7807_CR6","doi-asserted-by":"publisher","unstructured":"Lara PN Jr, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014;106:dju013. https:\/\/doi.org\/10.1093\/jnci\/dju013.","DOI":"10.1093\/jnci\/dju013"},{"key":"7807_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/iju.15063","volume":"30","author":"G Yamamichi","year":"2023","unstructured":"Yamamichi G, Kato T, Yumiba S, Tomiyama E, Koh Y, Nakano K, et al. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: a real-world multi-institutional study. Int J Urol. 2023;30:70\u20136. https:\/\/doi.org\/10.1111\/iju.15063.","journal-title":"Int J Urol"},{"key":"7807_CR8","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s11547-024-01843-6","volume":"129","author":"C Messina","year":"2024","unstructured":"Messina C, Fusco S, Gazzotti S, Albano D, Bonaccorsi G, Guglielmi G, et al. DXA beyond bone mineral density and the REMS technique: new insights for current radiologists practice. Radiol Med. 2024;129:1224\u201340. https:\/\/doi.org\/10.1007\/s11547-024-01843-6.","journal-title":"Radiol Med"},{"key":"7807_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2012.01.037","volume":"62","author":"D Ulmert","year":"2012","unstructured":"Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. 2012;62:78\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2012.01.037.","journal-title":"Eur Urol"},{"key":"7807_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"7807_CR11","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.euo.2025.06.002","volume":"8","author":"M Lunan-Taylor","year":"2025","unstructured":"Lunan-Taylor M, Raval AD, Nhan Phan NT, Korn MJ, Quintero V, McKay RR. Radium-223 in men with metastatic castration-resistant prostate cancer: a systematic literature review of real-world outcomes in observational studies. Eur Urol Oncol. 2025;8:1150\u201364. https:\/\/doi.org\/10.1016\/j.euo.2025.06.002.","journal-title":"Eur Urol Oncol"},{"key":"7807_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/iju.15078","volume":"30","author":"T Matsumoto","year":"2023","unstructured":"Matsumoto T, Hori Y, Shiota M, Blas L, Nakamura M, Seki N, et al. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: a multi-institutional study. Int J Urol. 2023;30:139\u201346. https:\/\/doi.org\/10.1111\/iju.15078.","journal-title":"Int J Urol"},{"key":"7807_CR13","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41391-025-00969-6","volume":"28","author":"AD Raval","year":"2025","unstructured":"Raval AD, Zhang Y, Korn M, Constantinovici N, McKay RR. Real-world utilization patterns and survival in men with metastatic prostate cancer treated with Radium-223 in the United States. Prostate Cancer Prostatic Dis. 2025;28:960\u20137. https:\/\/doi.org\/10.1038\/s41391-025-00969-6.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7807_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00259-022-06082-3","volume":"50","author":"K Kitajima","year":"2023","unstructured":"Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. Eur J Nucl Med Mol Imaging. 2023;50:1487\u201398. https:\/\/doi.org\/10.1007\/s00259-022-06082-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7807_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102784","volume":"15","author":"K Kitajima","year":"2023","unstructured":"Kitajima K, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S, et al. Assessing therapeutic response to Radium-223 with an automated bone scan index among metastatic castration-resistant prostate cancer patients: data from patients in the J-RAP-BSI Trial. Cancers (Basel). 2023;15:2784. https:\/\/doi.org\/10.3390\/cancers15102784.","journal-title":"Cancers (Basel)"},{"key":"7807_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041103","volume":"11","author":"MS De Feo","year":"2023","unstructured":"De Feo MS, Frantellizzi V, Bauckneht M, Farcomeni A, Filippi L, Rizzini EL, et al. The DAScis software for BSI calculation as a valuable prognostic tool in mCRPC treated with 223RaCl2: a multicenter Italian study. Biomedicines. 2023;11:1103. https:\/\/doi.org\/10.3390\/biomedicines11041103.","journal-title":"Biomedicines"},{"key":"7807_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00230","volume":"8","author":"PJ Saylor","year":"2024","unstructured":"Saylor PJ, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, et al. Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2024;8:e2300230. https:\/\/doi.org\/10.1200\/PO.23.00230.","journal-title":"JCO Precis Oncol"},{"key":"7807_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bco2.43","volume":"2","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Tsutsumi S, Kawahara T, Yasui M, Uemura K, Yoneyama S, et al. Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium-223. BJUI Compass. 2020;2:24\u201330. https:\/\/doi.org\/10.1002\/bco2.43.","journal-title":"BJUI Compass"},{"key":"7807_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2967\/jnumed.119.231100","volume":"61","author":"A Anand","year":"2020","unstructured":"Anand A, Tr\u00e4g\u00e5rdh E, Edenbrandt L, Beckman L, Svensson JH, Thellenberg C, et al. Assessing radiographic response to 223Ra with an automated bone scan index in metastatic castration-resistant prostate cancer patients. J Nucl Med. 2020;61:671\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.231100.","journal-title":"J Nucl Med"},{"key":"7807_CR20","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1158\/1078-0432.CCR-19-2591","volume":"26","author":"N Agarwal","year":"2020","unstructured":"Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, et al. Prospective evaluation of bone metabolic markers as surrogate markers of response to Radium-223 therapy in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2020;26:2104\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2591.","journal-title":"Clin Cancer Res"},{"key":"7807_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(18)30860-X.","journal-title":"Lancet Oncol"},{"key":"7807_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, et al. Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis. Eur Urol. 2025;87:285\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.027.","journal-title":"Eur Urol"},{"key":"7807_CR23","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s10147-025-02846-7","volume":"30","author":"N Masumori","year":"2025","unstructured":"Masumori N, Hosono M, Takahashi S, Kakehi Y, Uemura H, Sunaya T, et al. Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures. Int J Clin Oncol. 2025;30:2118\u201327. https:\/\/doi.org\/10.1007\/s10147-025-02846-7.","journal-title":"Int J Clin Oncol"},{"key":"7807_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142603","volume":"16","author":"SC Lin","year":"2024","unstructured":"Lin SC, Yu G, Corn PG, Damasco J, Lee YC, Song JH, et al. Radium-223 treatment produces prolonged suppression of resident osteoblasts and decreased bone mineral density in trabecular bone in osteoblast reporter mice. Cancers (Basel). 2024;16:2603. https:\/\/doi.org\/10.3390\/cancers16142603.","journal-title":"Cancers (Basel)"},{"key":"7807_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.euo.2023.09.015","volume":"7","author":"N Romero-Laorden","year":"2024","unstructured":"Romero-Laorden N, Lorente D, de Velasco G, Lozano R, Herrera B, Puente J, et al. Prospective assessment of bone metabolism biomarkers and survival in metastatic castration-resistant prostate cancer patients treated with radium-223: the PRORADIUM study. Eur Urol Oncol. 2024;7:447\u201355. https:\/\/doi.org\/10.1016\/j.euo.2023.09.015.","journal-title":"Eur Urol Oncol"},{"key":"7807_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01155-w","volume":"14","author":"M\u00d8 Fosb\u00f8l","year":"2024","unstructured":"Fosb\u00f8l M\u00d8, J\u00f8rgensen NR, Petersen PM, Kjaer A, Mortensen J. Biomarkers of bone metabolism in [223Ra] RaCl2 therapy - association with extent of disease and prediction of overall survival. EJNMMI Res. 2024;14:90. https:\/\/doi.org\/10.1186\/s13550-024-01155-w.","journal-title":"EJNMMI Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07807-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:33Z","timestamp":1779422913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07807-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7807"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07807-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The KYUCOG-1901 study was approved by the Certified Review Board, and registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol nos. UMIN000040358). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"M. Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer and research funding support from Astellas Pharma. T. Igawa received honoraria from Bayer. N. Masumori received honoraria from Bayer. M. Eto received honoraria from Takeda Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma and research funding support from Astellas Pharma, Sanofi, and Takeda Pharmaceutical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}